rs2233580 — PAX4 Arg192His

Missense variant that impairs PAX4's ability to repress insulin and glucagon promoters, reducing beta-cell mass and insulin secretion capacity; strongly associated with type 2 diabetes and younger age of onset in East and Southeast Asian populations

See your personal result for PAX4

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

PAX4 Arg192His — Impaired Beta-Cell Transcription Factor in East Asians

The pancreatic beta cell is a specialist — it exists for one purpose: sensing blood glucose and releasing exactly the right amount of insulin. Building and maintaining that specialization requires a master transcription factor called PAX4 (paired box gene 411 paired box gene 4
PAX4 controls beta-cell development and differentiation during embryogenesis and throughout life). When PAX4 function is compromised, the beta cell loses its identity, its capacity to produce insulin, and its ability to suppress glucagon — the hormone that keeps glucose rising between meals.

The rs2233580 variant encodes a single amino acid change in the PAX4 protein: arginine to histidine at position 192 (Arg192His). This is an East and Southeast Asian–specific variant, virtually absent in European and African populations. Among East Asians it reaches a minor allele frequency of roughly 9–10%, making it one of the most clinically significant population-specific diabetes risk variants known.

The Mechanism

PAX4 normally acts as a transcriptional repressor22 transcriptional repressor
a protein that binds to DNA and turns off neighboring genes. It binds the promoters of the insulin gene and the glucagon gene, keeping glucagon expression suppressed in beta cells while supporting insulin transcription. The Arg192His change sits in the homeodomain DNA-binding region of the protein and measurably weakens this repressor function. Luciferase reporter assays show that PAX4 R192H has significantly reduced ability to repress both the insulin and glucagon promoters compared to wild-type PAX4.

The downstream consequences are visible at the cellular level. In EndoC-βH1 beta cells, PAX4 knockdown impairs insulin secretion and reduces total insulin content. In CRISPR-derived hiPSC islet models33 CRISPR-derived hiPSC islet models
human induced pluripotent stem cells differentiated into islet-like structures in the lab, deletion or mutation of PAX4 causes de-repression of alpha-cell gene expression (particularly glucagon), an increase in polyhormonal "confused" cells, and reduced beta-cell identity markers. These phenotypes were fully rescued by CRISPR-mediated gene correction — confirming that Arg192His is the causal variant, not a passenger mutation.

The Evidence

The first genome-wide significant association came from a Chinese exome-chip study: 7,189 T2D cases and 10,813 controls in Hong Kong and Guangzhou, combined p = 3.74×10⁻¹⁵44 7,189 T2D cases and 10,813 controls in Hong Kong and Guangzhou, combined p = 3.74×10⁻¹⁵
Guo et al. Exome-chip association analysis reveals an Asian-specific missense variant in PAX4 associated with type 2 diabetes in Chinese individuals. Diabetologia, 2017.

A large study of early-onset T2D in Chinese found that 21.4% of 2,886 patients with early-onset T2D carried at least one Arg192His allele55 21.4% of 2,886 patients with early-onset T2D carried at least one Arg192His allele
Ma et al. Missense variants in PAX4 are associated with early-onset diabetes in Chinese. Diabetes Therapy, 2021. The combined odds ratio was 1.88 (95% CI 1.37–2.60). Carriers showed higher HbA1c, lower 2-hour C-peptide levels, and a dose-dependent shift toward younger age of diagnosis.

Functional confirmation came from a 2023 Nature Communications study using isogenic hiPSC lines carrying the Arg192His allele: participants heterozygous or homozygous for p.His192 showed decreased acute insulin response to glucose and reduced HOMA-B beta-cell function66 participants heterozygous or homozygous for p.His192 showed decreased acute insulin response to glucose and reduced HOMA-B beta-cell function
Hastoy et al. PAX4 loss of function increases diabetes risk by altering human pancreatic endocrine cell development. Nature Communications, 2023.

A Singapore cohort study among East Asians confirmed the association with younger age of T2D onset and reduced C-peptide77 association with younger age of T2D onset and reduced C-peptide
Ang et al. PAX4 R192H is associated with younger onset of type 2 diabetes in East Asians in Singapore. Diabetes Research and Clinical Practice, 2019.

One pharmacogenomic study found that patients with the CC genotype (Arg/Arg) achieved significantly better fasting glucose control on sulfonylurea monotherapy than CT or TT carriers88 CC genotype (Arg/Arg) achieved significantly better fasting glucose control on sulfonylurea monotherapy than CT or TT carriers
Chen et al. Effects of TCF7L2 rs7903146 and PAX4 rs2233580 on hypoglycemic agent therapeutic efficacy. Heliyon, 2024.

Practical Actions

Carriers of one or two T alleles have measurably reduced beta-cell function. The core implication is impaired glucose-stimulated insulin secretion. Dietary patterns that minimize postprandial glucose spikes directly reduce the demand placed on already-compromised beta cells. Monitoring for early metabolic changes (fasting glucose, HbA1c, fasting insulin) is warranted, especially in East Asian individuals who carry the variant — since the risk is population-concentrated, it is most clinically relevant for this group.

Carriers may have reduced benefit from sulfonylureas (which act by stimulating beta-cell insulin release) compared to biguanides (which improve insulin sensitivity), though this pharmacogenomic finding is preliminary and should be discussed with a prescribing physician.

Interactions

PAX4 rs2233580 (R192H) and rs3824004 (R192S) affect the same amino acid position 192 in the PAX4 homeodomain. Among East Asians, compound heterozygous carriers of one R192H and one R192S allele show dramatically higher T2D risk (OR ~3.23 vs OR ~1.78 for single-variant carriers), as documented in Ma et al. 2021 (PMID 33216280). This compound effect is worth flagging in genetic counseling for East Asian patients with early-onset T2D.

Both PAX4 rs2233580 and TCF7L2 rs7903146 affect beta-cell insulin secretion through distinct mechanisms (transcription factor function vs. Wnt/incretin pathway), and their combination in a patient informs differential response to first-line oral diabetes medications.

Genotype Interpretations

What each possible genotype means for this variant.

CC Normal PAX4 Function Normal

Normal PAX4 transcription factor activity

You carry the common Arg/Arg genotype at PAX4 position 192 — both copies of your PAX4 gene encode the standard arginine residue. PAX4's repressor function at the insulin and glucagon promoters is intact. This is the most frequent genotype in all non-East Asian populations and in approximately 83% of East Asians. You do not carry the East Asian–specific elevated T2D risk associated with this variant.

CT One Risk Allele Intermediate

One copy of the PAX4 Arg192His variant — modestly elevated beta-cell dysfunction risk

The Arg192His missense change weakens PAX4's ability to bind its DNA targets in the insulin and glucagon promoters. One functional copy and one impaired copy means your overall PAX4 activity is intermediate. The additive inheritance means even a single copy shifts the beta-cell phenotype. In the 2023 Nature Communications functional study, heterozygous carriers showed decreased acute insulin response to intravenous glucose (padj = 0.036) and reduced HOMA-B (padj = 0.027) even in the non-diabetic state — meaning the subclinical reduction in beta-cell reserve is detectable before diabetes develops. Pharmacogenomically, the C/C genotype responds better to sulfonylureas than CT or TT genotypes in preliminary studies; if you are East Asian and ever prescribed sulfonylurea therapy for diabetes, this is worth discussing with your physician.

TT Two Risk Alleles High Risk

Two copies of the PAX4 Arg192His variant — substantially elevated T2D risk

The homeodomain of PAX4 at residue 192 makes direct contact with its DNA target sequences. Replacing both arginines with histidine means neither PAX4 copy can effectively bind the insulin or glucagon promoters. Alpha-cell gene expression is de-repressed; polyhormonal cells increase; beta-cell insulin stores are reduced. Clinically, this manifests as lower fasting C-peptide and blunted C-peptide response to oral glucose challenge — measurable even in non-diabetic TT carriers. The risk is most pronounced in East Asian individuals and those of Southeast Asian descent (Thai, Korean, Chinese, Singaporean populations where the variant is concentrated). In the Singapore cohort, T allele dose correlated with progressively younger age at T2D diagnosis.

Pharmacogenomically, TT carriers show the weakest glycemic response to sulfonylurea monotherapy, while biguanide (metformin) response appears genotype-independent. Given that beta-cell functional reserve is low, strategies that reduce peripheral insulin demand (insulin sensitizers, GLP-1 agonists) may be more effective than strategies that further stimulate an already-impaired secretory apparatus.